Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7921| Empirical Antibiotic Prescribing in Adult COVID-19 Inpatients over Two Years in Mexico | |
| AGUSTIN LUGO-RADILLO Monica Rios_Silva Efrén Murillo-Zamora XÓCHITL TRUJILLO TRUJILLO Miguel Huerta Oliver Mendoza-Cano José Guzmán Esquivel José Alejandro Guzmán-Solórzano MARIA REGINA OCHOA CASTRO ALAN GABRIEL ORTEGA MACÍAS ANDREA LIZETH ZEPEDA ANAYA VALERIA RUIZ MONTES DE OCA | |
| Acceso Abierto | |
| Atribución | |
| https://doi.org/10.3390/antibiotics11060764 | |
| Background and Objectives: Empirical antibiotic prescribing in patients with coronavirus disease 2019 (COVID-19) has been common even though bacterial coinfections are infrequent. The overuse of antibacterial agents may accelerate the antibiotic resistance crisis. We aimed to evalu- ate factors predicting empirical antibiotic prescribing to adult COVID-19 inpatients over 2 years (March 2020 –February 2021) in Mexico. Materials and Methods: A cross-sectional analysis of a na- tionwide cohort study was conducted. Hospitalized adults due to laboratory-confirmed COVID-19 were included (n = 214,171). Odds ratios (OR) and 95% confidence intervals (CI), computed by using logistic regression models, were used to evaluate factors predicting empirical antibiotic prescribing. Results: The overall frequency of antibiotic usage was 25.3%. In multiple analysis, the highest risk of antibiotic prescription was documented among patients with pneumonia at hospital admission (OR = 2.20, 95% CI 2.16–2.25). Male patients, those with chronic comorbidities (namely obesity and chronic kidney disease) and longer interval days from symptoms onset to healthcare seeking, were also more likely to receive these drugs. We also documented that, per each elapsed week during the study period, the odds of receiving antibiotic therapy decreased by about 2% (OR = 0.98, 95% CI 0.97–0.99). Conclusion: Our study identified COVID-19 populations at increased risk of receiving empirical antibiotic therapy during the first two years of the pandemic | |
| Antibiotics | |
| 02-06-2022 | |
| Artículo | |
| https://www.mdpi.com/ | |
| Inglés | |
| Murillo-Zamora, E.; Trujillo, X.; Huerta, M.; Mendoza-Cano, O.; Guzmán-Esquivel, J.; Guzmán-Solórzano, J.A.; Ochoa-Castro, M.R.; Ortega-Macías, A.G.; Zepeda-Anaya, A.L.; Ruiz-Montes de Oca, V.; et al. Empirical Antibiotic Prescribing in Adult COVID-19 Inpatients over Two Years in Mexico. Antibiotics 2022, 11, 764. https://doi.org/10.3390/ antibiotics11060764 | |
| VIRUS RESPIRATORIOS | |
| Versión publicada | |
| publishedVersion - Versión publicada | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Empirical Antibiotic Prescribing in Adult COVID-19 Inpatients over Two Years in Mexico.pdf | 468.59 kB | Adobe PDF | Visualizar/Abrir |